News Release

Women receive less recommended drugs after a heart attack

Peer-Reviewed Publication

European Society of Cardiology

Sophia Antipolis - 17 April 2020: Women are more likely to die after a heart attack than men because they are often not prescribed the drugs they need. That's the result of research presented today on ACVC Essentials 4U, a scientific platform of the European Society of Cardiology (ESC).

"Female heart attack patients may appear more fragile to physicians since they are often older than men, with smaller bodies and more co-existing conditions such as diabetes and kidney disease," said study author Dr. Claudio Montalto of the University of Pavia, Italy. "Therefore, I think doctors might avoid potent antiplatelets (a type of blood thinner) and aggressive blood pressure lowering."

The study prospectively enrolled 1,523 patients diagnosed with a heart attack between 2015 and 2017, including 471 (31%) women and 1,052 (69%) men. Prescribed medications were recorded, as were any medical reasons why a drug should not be prescribed (called contraindications).

Women were more likely to die after a heart attack than men. Rates of in-hospital death were similar between sexes but after an average 264-day follow-up, more women than men had died. "Previous studies have already established excess deaths in female heart attack patients, so we expected this result," said Dr. Montalto.

A significantly lower proportion of women received optimal medical therapy at discharge (55% of women versus 64% of men). Women were also less likely to undergo invasive procedures than men (71% of women versus 83% of men).

Dr. Montalto said: "It is well established that optimal medical therapy and invasive management are both associated with increased survival after myocardial infarction. Therefore, we then examined whether female patients had worse survival strictly due to their sex - which means genetic and hormonal status, and so on - or because of suboptimal treatment."

Using 'multivariable regression', a type of statistical analysis, it was observed that receiving optimal medical therapy after a heart attack was independently associated with a roughly 50% decrease in all-cause death, while female sex was not an independent predictor of death after a heart attack.

"Our study suggests that it is not being female that causes more deaths, but it is receiving fewer recommended drugs," said Dr. Montalto. "In fact, getting the right medication nearly halves the risk of dying."

Dr. Montalto noted that a strength the study was collecting data on contraindications. "This enabled us to discriminate whether non-prescription of a drug was due to a contraindication or not," he said.

Dr. Montalto concluded: "Appropriate drug prescription is easily improved with increased knowledge of guideline recommendations and closer attention to contraindications to drug therapy. Our study indicates that these actions could improve the outcome of female heart attack patients."


Authors: ESC Press Office
Tel: +33 (0)4 89 87 20 85
Mobile: +33 (0)7 8531 2036
Follow us on Twitter @ESCardioNews

Notes to editor

Check the rapidly expanding ESC resources on COVID-19 and cardiology at

Funding: The registry was sponsored by an unconditional grant from AstraZeneca.

Disclosures: None.

About the Acute Cardiovascular Care Association

The Acute Cardiovascular Care Association (ACVC) is a branch of the ESC. Its mission is to improve the quality of care and outcomes of patients with acute cardiovascular diseases.

About ACVC Essentials 4U #ACVCessentials4U

ACVC Essentials 4U is a platform for scientific content related to acute cardiovascular care. New content will be added regularly.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.